46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03188081 (ClinicalTrials.gov) | August 4, 2017 | 12/6/2017 | A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept | A Prospective, Multicentric, Observational Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life RA Patients Treated With Abatacept SC | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Recruiting | 18 Years | N/A | All | 300 | Italy | |
| 2 | NCT02598466 (ClinicalTrials.gov) | July 2015 | 4/11/2015 | Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa | Patient-Reported Efficacy of Subcutaneous Abatacept in Rheumatoid Arthritis: An Evaluation Of Patients In a Compassionate Use Programme in South Africa | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | Hexor, South Africa | Completed | 18 Years | N/A | Both | 69 | N/A | NULL |
| 3 | NCT01001832 (ClinicalTrials.gov) | December 2009 | 26/10/2009 | Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients | A Phase II/III, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Assess Similarity of the Efficacy, Pharmacokinetics, Safety and Immunogenicity of Abatacept Administered Subcutaneously or Intravenously in Japanese Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate | Rheumatoid Arthritis | Drug: Intravenous (IV) abatacept;Drug: Subcutaneous (SC) abatacept | Bristol-Myers Squibb | NULL | Completed | 20 Years | N/A | All | 118 | Phase 2/Phase 3 | Japan |
| 4 | NCT00559585 (ClinicalTrials.gov) | January 2008 | 15/11/2007 | Methotrexate-Inadequate Response Study | A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate | Rheumatoid Arthritis (RA) | Drug: Subcutaneous (SC) Abatacept;Drug: Intravenous (IV) Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 2492 | Phase 3 | United States;Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;Austria;Spain;Chile |